Christine Herforth1, Sean P Stroup1,2,3, Zinan Chen4,5, Lauren E Howard4,5, Stephen J Freedland6,5, Daniel M Moreira7, Martha K Terris4,5, William J Aronson8,9, Matthew R Cooperberg10,11, Christopher L Amling12, Christopher J Kane2,3,13. 1. Department of Urology, Naval Medical Center San Diego, San Diego, CA, USA. 2. Department of Urology, University of California, San Diego, CA, USA. 3. Section of Urologic Oncology, Moores UCSD Cancer Center, La Jolla, CA, USA. 4. Duke University, Durham, NC, USA. 5. Veterans Affairs Durham Medical Center, Durham, NC, USA. 6. Cedars-Sinai Medical Center, Los Angeles, CA, USA. 7. The Mayo Clinic, Rochester, MN, USA. 8. University of California, Los Angeles, CA, USA. 9. Veteran Affairs Los Angeles, Los Angeles, CA, USA. 10. University of California, San Francisco, CA, USA. 11. Veterans Affairs San Francisco Medical Center, San Francisco, CA, USA. 12. Oregon Health and Science University, Portland, OR, USA. 13. Veterans Affairs San Diego Medical Center, La Jolla, CA, USA.
Abstract
OBJECTIVE: To evaluate biochemical recurrence (BCR) patterns amongst men undergoing radical prostatectomy (RP) with specimens having negative (NSM), positive (PSM), and close surgical margins (CSM) from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort, as PSM after RP are a significant predictor of biochemical failure and possible disease progression, with CSM representing a diagnostic challenge for surgeons. PATIENTS AND METHODS: Men undergoing RP between 1988 and 2015 with known final pathological margin status were evaluated. The cohort was divided into three groups based on margin status; NSM, PSM, and CSM. CSM were defined by distance of tumour ≤1 mm from the surgical margin. BCR was defined as a prostate-specific antigen (PSA) level of >0.2 ng/mL, two values at 0.2 ng/mL, or secondary treatment for an elevated PSA level. Predictors of BCR, metastases, and mortality were analysed using Cox proportional hazard models. RESULTS: Of 5515 men in the SEARCH database, 4337 (79%) men met criteria for inclusion in the analysis. Of these, 2063 (48%) had NSM, 1902 (44%) had PSM, and 372 (8%) had CSM. On multivariable analysis, relative to NSM, men with CSM had a higher risk of BCR (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.25-1.82; P < 0.001) but a decreased risk of BCR when compared to those men with PSM (HR 2.09, 95% CI 1.86-2.36; P < 0.001). Metastases, prostate cancer-specific mortality and all-cause mortality did not differ based on margin status alone. CONCLUSIONS: Management of men with CSM is a diagnostic challenge, with a disease course that is not entirely benign. The evaluation of other known risk factors probably provides greater prognostic value for these men and may ultimately better select those who may benefit from adjuvant therapy.
OBJECTIVE: To evaluate biochemical recurrence (BCR) patterns amongst men undergoing radical prostatectomy (RP) with specimens having negative (NSM), positive (PSM), and close surgical margins (CSM) from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort, as PSM after RP are a significant predictor of biochemical failure and possible disease progression, with CSM representing a diagnostic challenge for surgeons. PATIENTS AND METHODS: Men undergoing RP between 1988 and 2015 with known final pathological margin status were evaluated. The cohort was divided into three groups based on margin status; NSM, PSM, and CSM. CSM were defined by distance of tumour ≤1 mm from the surgical margin. BCR was defined as a prostate-specific antigen (PSA) level of >0.2 ng/mL, two values at 0.2 ng/mL, or secondary treatment for an elevated PSA level. Predictors of BCR, metastases, and mortality were analysed using Cox proportional hazard models. RESULTS: Of 5515 men in the SEARCH database, 4337 (79%) men met criteria for inclusion in the analysis. Of these, 2063 (48%) had NSM, 1902 (44%) had PSM, and 372 (8%) had CSM. On multivariable analysis, relative to NSM, men with CSM had a higher risk of BCR (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.25-1.82; P < 0.001) but a decreased risk of BCR when compared to those men with PSM (HR 2.09, 95% CI 1.86-2.36; P < 0.001). Metastases, prostate cancer-specific mortality and all-cause mortality did not differ based on margin status alone. CONCLUSIONS: Management of men with CSM is a diagnostic challenge, with a disease course that is not entirely benign. The evaluation of other known risk factors probably provides greater prognostic value for these men and may ultimately better select those who may benefit from adjuvant therapy.
Authors: Kamyar Ghabili; Henry S Park; James B Yu; Preston C Sprenkle; Simon P Kim; Kevin A Nguyen; Xiaomei Ma; Cary P Gross; Michael S Leapman Journal: World J Urol Date: 2020-06-19 Impact factor: 4.226
Authors: Judith Olde Heuvel; Berlinda J de Wit-van der Veen; Henk G van der Poel; Pim J van Leeuwen; Elise M Bekers; Maarten R Grootendorst; Kunal N Vyas; Cornelis H Slump; Marcel P M Stokkel Journal: J Nucl Med Date: 2021-04-30 Impact factor: 11.082
Authors: Christina Hunter Chapman; Megan E V Caram; Archana Radhakrishnan; Alexander Tsodikov; Curtiland Deville; Jennifer Burns; Alexander Zaslavsky; Michael Chang; John T Leppert; Timothy Hofer; Anne E Sales; Sarah T Hawley; Brent K Hollenbeck; Ted A Skolarus Journal: Cancer Med Date: 2019-11-05 Impact factor: 4.452
Authors: Serdar Celik; Anıl Eker; İbrahim Halil Bozkurt; Deniz Bolat; İsmail Basmacı; Ertuğrul Şefik; Tansu Değirmenci; Bülent Günlüsoy Journal: Prostate Int Date: 2020-09-17